PUBLIC COMPANY
save$WVEWave Life Sciences Ltd.
$WVE5.4100+4.04%Singapore, SGupdated 3h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
- phase1A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
- phase2Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
- phase1A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
- phase2Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- phase2Study of WVE-003 in Patients With Huntington's Disease
- phase2Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
- phase2Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Mar 23, 26cTAKANASHI KEN · director3,901,348 sh
- Mar 23, 26cTAKANASHI KEN · director3,901,348 sh
- Feb 26, 26option exerciseFrancis Chris · See Remarks15,294 sh
- Feb 26, 26option exerciseFrancis Chris · See Remarks17,900 sh
- Feb 26, 26option exerciseFrancis Chris · See Remarks17,900 sh
- Feb 26, 26option exerciseFrancis Chris · See Remarks15,294 sh
🐶 Hiring Signal
News
- With $263M, LifeMine unearths a new drug for organ transplantsLed by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.biopharma_dive · 8d ago
- ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series EA little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking…fiercebiotech · 9d ago
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 17d ago
- Wave aims for monthly dosing with RNA editing treatment for AATDWave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. Peo…endpoints · 2mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that